NeoStem rated "outperform" by Cowen Print E-mail
By Deborah Sterescu, ProactiveInvestors.com   
Thursday, 24 March 2011 16:05
NeoStem (AMEX:NBS) has been given an initial "outperform" rating from equity research firm Cowen, based on recent acquisitions and tie ups strengthening the company's adult stem cell banking capabilities.

The recent purchase of Progentior Cell Therapy, said Cowen, gives NeoStem a "comprehensive" platform from which to grow its US cord blood and adult stem cell banking, as well as cellular manufacturing and therapeutic businesses.

Progenitor has cell therapy manufacturing facilities, as well as processing and storage facilities for stem cells collected from the umbilical cord at birth, located on the east and west coast of the US.

Following the acquisition of Progenitor, NeoStem launched new storage services that will be bundled together as a multi-generational banking program, to be called the "Family Plan".

Nowadays, many seek to collect and store their own stem cells and those collected from the umbilical cord at birth for future medical use. These stem cells can be used to help cure a wide range of diseases, such as leukemia, lymphoma, and future potential applications including heart disease and diabetes.

Cowen also noted in its research report that aside from its US services, NeoStem also has partnerships with two "prominent" Chinese hospitals, giving it a foundation on which to build its China stem-cell therapy business.

"In fact, [NeoStem's] current valuation could be justified based alone on its 51% stake in Suzhou Erye, a Chinese generic drug business which is estimated to record sales of approximately $90MM in 2011," Cowen concluded.

According to the equity research firm, antibiotics manufacturer Suzhou Erye is poised to benefit from strong domestic market growth of over 20% per year, and the Chinese government's ongoing $125 billion healthcare reform expenditure, which should provide NeoStem with cash flow to reinvest in the stem-cell business.

NeoStem's shares rose nearly 5% on Thursday to $1.69 as of 3:11pm EST.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter